Disease Markers

Research Article

Urinary Matrix Metalloproteinase-7 and Prediction of AKI Progression Post Cardiac Surgery

Table 2

Postoperative characteristics and outcomes of patients with and without AKI progression^a.


	AKI progression
	Yes ()	No ()

Time of AKI
Within 3 days after surgery, (%)	28 (100.0)	88 (94.6)	0.59
SCr on the day of AKI diagnosis (μmol/L)			<0.001
Change of SCr on the day of AKI (μmol/L)^b			<0.001
Change of SCr on the day of AKI (%)^c			0.01
Biomarkers on the day of AKI diagnosis
uMMP-7 (μg/g Cr)	10.4 (5.6-25.7)	3.3 (1.3-7.3)	<0.001
uIL-18 (ng/g Cr)	305.5 (155.7-596.0)	110.9 (32.9-232.0)	<0.001
uNGAL (μg/g Cr)	146.6 (31.4-391.9)	50.8 (19.8-113.6)	0.01
UACR (mg/g Cr)	163.8 (84.1-312.9)	39.8 (16.2-100.7)	<0.001
Outcomes
Acute dialysis, (%)	5 (17.9)	0 (0.0)	<0.001
In-hospital death, (%)	4 (14.3)	0 (0.0)	0.002

^aAKI progression is defined as worsening of the AKI stage (stage 1 to either stage 2 or stage 3 or from stage 2 to stage 3). ^bSerum creatinine level on the day of AKI diagnosis minus baseline serum creatinine level. ^c. Abbreviation: SCr: serum creatinine; uMMP-7: urinary matrix metalloproteinase-7; uIL-18: urinary interleukin-18; uNGAL: urinary neutrophil gelatinase-associated lipocalin; UACR: urinary albumin to creatinine ratio.